28,463 Shares in Jazz Pharmaceuticals PLC $JAZZ Bought by Entropy Technologies LP

Entropy Technologies LP acquired a new position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 28,463 shares of the specialty pharmaceutical company’s stock, valued at approximately $4,839,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of JAZZ. Vestal Point Capital LP acquired a new stake in shares of Jazz Pharmaceuticals in the 2nd quarter valued at about $127,344,000. Goldentree Asset Management LP acquired a new stake in shares of Jazz Pharmaceuticals in the 3rd quarter valued at about $149,597,000. Franklin Resources Inc. raised its stake in shares of Jazz Pharmaceuticals by 164.0% in the 4th quarter. Franklin Resources Inc. now owns 1,818,911 shares of the specialty pharmaceutical company’s stock valued at $309,215,000 after purchasing an additional 1,129,995 shares during the period. Bank of New York Mellon Corp raised its stake in shares of Jazz Pharmaceuticals by 160.2% in the 4th quarter. Bank of New York Mellon Corp now owns 1,161,857 shares of the specialty pharmaceutical company’s stock valued at $197,516,000 after purchasing an additional 715,361 shares during the period. Finally, Schonfeld Strategic Advisors LLC raised its stake in shares of Jazz Pharmaceuticals by 592.1% in the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 436,443 shares of the specialty pharmaceutical company’s stock valued at $57,523,000 after purchasing an additional 373,383 shares during the period. Institutional investors and hedge funds own 89.14% of the company’s stock.

Insider Buying and Selling

In other news, Director Bruce C. Cozadd sold 6,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $190.50, for a total transaction of $1,143,000.00. Following the sale, the director owned 384,682 shares in the company, valued at $73,281,921. This represents a 1.54% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Neena M. Patil sold 1,200 shares of the company’s stock in a transaction that occurred on Wednesday, June 10th. The stock was sold at an average price of $231.83, for a total value of $278,196.00. Following the sale, the executive vice president owned 51,549 shares in the company, valued at approximately $11,950,604.67. This represents a 2.27% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 11,941 shares of company stock worth $2,565,339. 4.10% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several analysts have issued reports on JAZZ shares. UBS Group raised Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their price target for the company from $188.00 to $307.00 in a research note on Tuesday, May 19th. TD Cowen lifted their price target on Jazz Pharmaceuticals from $220.00 to $275.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. Leerink Partners lifted their price target on Jazz Pharmaceuticals from $215.00 to $225.00 and gave the company an “outperform” rating in a research note on Wednesday, April 22nd. Bank of America lifted their price target on Jazz Pharmaceuticals from $281.00 to $307.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Weiss Ratings raised Jazz Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, May 26th. Sixteen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Jazz Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $246.06.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ JAZZ opened at $230.56 on Monday. The stock has a market capitalization of $14.48 billion, a price-to-earnings ratio of -11,522.24, a PEG ratio of 0.20 and a beta of 0.32. The business has a 50-day moving average of $217.61 and a 200-day moving average of $188.90. The company has a debt-to-equity ratio of 0.95, a current ratio of 2.04 and a quick ratio of 1.85. Jazz Pharmaceuticals PLC has a fifty-two week low of $105.00 and a fifty-two week high of $243.32.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share for the quarter. The firm had revenue of $1.07 billion for the quarter. Jazz Pharmaceuticals had a return on equity of 14.56% and a net margin of 0.66%. As a group, sell-side analysts predict that Jazz Pharmaceuticals PLC will post 22.09 earnings per share for the current fiscal year.

Jazz Pharmaceuticals News Summary

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Negative Sentiment: Jazz Pharmaceuticals said the Phase 3 LAGOON trial for Zepzelca did not meet its primary endpoint of overall survival in second-line small cell lung cancer. Jazz Pharmaceuticals Provides Update on Zepzelca (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer
• Negative Sentiment: Reuters reported the trial failure could put Zepzelca’s current regulatory status at risk, raising uncertainty around a key oncology asset. Jazz Pharmaceuticals lung cancer drug fails main trial goal
• Negative Sentiment: Industry coverage from multiple outlets reinforced the setback, suggesting investor concern may persist until Jazz clarifies next steps for Zepzelca. Jazz Pharma announces late-stage trial setback for lung cancer therapy
• Negative Sentiment: FiercePharma noted the latest twist in the Zepzelca saga, highlighting the importance of the drug to Jazz’s cancer franchise and the market’s negative reaction to the failure. In latest twist in Zepzelca saga, Jazz and PharmaMar lung cancer drug fails phase 3 test
• Negative Sentiment: Separately, an SEC filing showed EVP Neena M. Patil sold 1,200 shares earlier this week, a small insider sale that may add to cautious sentiment. Jazz Pharmaceuticals PLC EVP Neena M. Patil sold shares
• Neutral Sentiment: Some recent commentary still frames Jazz as a value stock with a “moderate buy” analyst consensus, but this is being overshadowed by the trial disappointment. Why Jazz Pharmaceuticals (JAZZ) is a Top Value Stock for the Long-Term

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.